SCHEMBL15917642

SCHEMBL15917642

Clc1nccc(NCc2cccc(Oc3cnccn3)c2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 10/20 0.45
CYP1A2 P05177 8/20 0.45
CYP3A4 P08684 8/20 0.45
CYP2C19 P33261 8/20 0.45
CYP2D6 P10635 7/20 0.45
ALDH1A1 P00352 7/20 0.45
TSHR P16473 5/20 0.45
HSD17B10 Q99714 3/20 0.45
LMNA P02545 2/20 0.45
DYRK1A Q13627 4/20 0.43
ALOX15 P16050 4/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
HPGD P15428 2/20 0.43
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
CYP2C9 P11712 2/20 0.41
USP2 O75604 2/20 0.41
MAPT P10636 2/20 0.41
MAOA P21397 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14554926 0.84 CLK4 (0.51) CLK4CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL14554910 0.80 CLK4 (0.51) CLK4CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL28114877 0.80 CLK4 (0.61) CLK4CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL14554891 0.79 CLK4 (0.62) CLK4CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL14554941 0.78 CLK4 (0.48) CLK4CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL25588033 0.77 PRMT6 (0.50) ALDH1A1TSHRMEN1KMT2AMAPT
SCHEMBL4554748 0.75 MAP4K4 (0.54) CLK4CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL27209672 0.75 GAA (0.46) ALDH1A1LMNASMN1; SMN2TDP1MEN1
SCHEMBL25584924 0.75 MAPK1 (0.47) ALDH1A1SMN1; SMN2TDP1MEN1KMT2A
SCHEMBL14438360 0.74 ALDH1A1 (0.46) ALDH1A1TSHRMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9199962-B2 Substituted azaheterocycles for the treatment of cancer MERCK PATENT GMBH (DE) 2015-12-01 US disclosed
US-9199962-B2 Substituted azaheterocycles for the treatment of cancer MERCK PATENT GMBH (DE) 2015-12-01 US disclosed
US-9199962-B2 Substituted azaheterocycles for the treatment of cancer MERCK PATENT GMBH (DE) 2015-12-01 US disclosed
US-20140221366-A1 Substituted Azaheterocycles for the Treatment of Cancer MERCK PATENT GMBH (DE) 2014-08-07 US disclosed
US-20140221366-A1 Substituted Azaheterocycles for the Treatment of Cancer MERCK PATENT GMBH (DE) 2014-08-07 US disclosed
US-20140221366-A1 Substituted Azaheterocycles for the Treatment of Cancer MERCK PATENT GMBH (DE) 2014-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221366-A1 Substituted Azaheterocycles for the Treatment of Cancer CCNH, CCNA1, MYC CLK4 4593/4885CYP1A2 584/4885CYP3A4 2492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.